(Press-News.org) Small pieces of synthetic RNA trigger a RNA interference (RNAi) response that holds great therapeutic potential to treat a number of diseases, especially cancer and pandemic viruses. The problem is delivery -- it is extremely difficult to get RNAi drugs inside the cells in which they are needed. To overcome this hurdle, researchers at University of California, San Diego School of Medicine have developed a way to chemically disguise RNAi drugs so that they are able to enter cells. Once inside, cellular machinery converts these disguised drug precursors -- called siRNNs -- into active RNAi drugs. The technique will publish Nov. 17 in Nature Biotechnology.
"Many current approaches use nanoparticles to deliver RNAi drugs into cells," said Steven F. Dowdy, PhD, professor in the Department of Cellular and Molecular Medicine and the study's principal investigator. "While nanotechnology protects the RNAi drug, from a molecular perspective nanoparticles are huge, some 5,000 times larger than the RNAi drug itself. Think of delivering a package into your house by having an 18-wheeler truck drive it through your living room wall -- that's nanoparticles carrying standard RNAi drugs. Now think of a package being slipped through the mail slot -- that's siRNNs."
The beauty of RNAi is that it selectively blocks production of target proteins in a cell, a finding that garnered a Nobel Prize in 2006. While this is a normal process that all cells use, researchers have taken advantage of RNAi to inhibit specific proteins that cause disease when overproduced or mutated, such as in cancer. First, researchers generate RNAi drugs with a sequence that corresponds to the gene blueprint for the disease protein and then delivers them into cells. Once inside the cell, the RNAi drug is loaded into an enzyme that specifically slices the messenger RNA encoding the target protein in half. This way, no protein is produced.
As cancer and viral genes mutate, RNAi drugs can be easily evolved to target them. This allows RNAi therapy to keep pace with the genetics of the disease -- something that no other type of therapy can do. Unfortunately, due to their size and negatively charged chemical groups (phosphates) on their backbone, RNAi drugs are repelled by the cellular membrane and cannot be delivered into cells without a special delivery agent.
It took Dowdy and his team, including Bryan Meade, PhD, Khirud Gogoi, PhD, and Alexander S. Hamil, eight years to find a way to mask RNAi's negative phosphates in such a way that gets them into cells, but is still capable of inducing an RNAi response once inside.
In the end, the team added a chemical tag called a phosphotriester group. The phosphotriester neutralizes and protects the RNA backbone -- converting the ribonucleic acid (RNA) to ribonucleic neutral (RNN), and thus giving the name siRNN. The neutral (uncharged) nature of siRNNs allows them to pass into the cell much more efficiently. Once inside the cell, enzymes cleave off the neutral phosphotriester group to expose a charged RNAi drug that shuts down production of the target disease protein. siRNNs represent a transformational next-generation RNAi drug.
"siRNNs are precursor drugs, or prodrugs, with no activity. It's like having a tool still in the box, it won't work until you take it out," Dowdy said. "Only when the packaging -- the phosphotriester groups -- is removed inside the cells do you have an active tool or RNAi drug."
The findings held up in a mouse model, too. There, Dowdy's team found that siRNNs were significantly more effective at blocking target protein production than typical RNAi drugs -- demonstrating that once siRNNs get inside a cell they can do a better job.
"There remains a lot of work ahead to get this into the clinics. But, in theory, the therapeutic potential of siRNNs is endless," Dowdy said. "Particularly for cancer, viral infections and genetic diseases."
The siRNN technology forms the basis for Solstice Biologics, a biotech company in La Jolla, Calif. that is now taking the technique to the next level. Dowdy is a co-founder of Solstice Biologics and serves as a Board Director.
INFORMATION:
Additional study co-authors include Caroline Palm-Apergi, Arjen van den Berg, Jonathan C. Hagopian, Aaron D. Springer, Akiko Eguchi, Apollo D. Kacsinta, Connor F. Dowdy, Asaf Presente, Peter Lönn, Manuel Kaulich, Naohisa Yoshioka, Edwige Gros and Xian-Shu Cui, UC San Diego School of Medicine.
This research was funded in part by the W.M. Keck Foundation, U.S. Department of Defense, Leukemia & Lymphoma Society, Pardee Foundation and Howard Hughes Medical Institute.
Northwestern Medicine scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer.
By inhibiting the tumor-forming consequences of the mutation using an experimental drug called GSKJ4, they delayed tumor growth and prolonged survival in mice with pediatric brainstem glioma.
Also known as diffuse intrinsic pontine glioma (DIPG), the disease occurs when tumors form in the brainstem, which controls essential body functions such as breathing, heartbeat and motor and ...
BOSTON - A research team led by Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes. Their results, published in the November 17, 2014 advance online issue of the journal Nature, shed additional light on how a longstanding class of diabetes drugs, known as thiazolidinediones (TZDs), work to improve glucose metabolism and suggest that inhibitors of the signaling pathway -- known ...
PROVIDENCE, R.I. [Brown University] -- Ample evidence of ancient rivers, streams, and lakes make it clear that Mars was at some point warm enough for liquid water to flow on its surface. While that may conjure up images of a tropical Martian paradise, new research published today in Nature Geoscience throws a bit of cold water on that notion.
The study, by scientists from Brown University and Israel's Weizmann Institute of Science, suggests that warmth and water flow on ancient Mars were probably episodic, related to brief periods of volcanic activity that spewed tons ...
A team of New York University and University of Barcelona physicists has developed a method to control the movements occurring within magnetic materials, which are used to store and carry information. The breakthrough could simultaneously bolster information processing while reducing the energy necessary to do so.
Their method, reported in the most recent issue of the journal Nature Nanotechnology, manipulates "spin waves," which are waves that move in magnetic materials. Physically, these spin waves are much like water waves--like those that propagate on the surface ...
In what is likely to be a major step forward in the study of influenza, cystic fibrosis and other human diseases, an international research effort has a draft sequence of the ferret genome. The sequence was then used to analyze how the flu and cystic fibrosis affect respiratory tissues at the cellular level.
The National Institute of Allergy and infectious Diseases, of the National Institutes of Health, funded the project that was coordinated by Michael Katze and Xinxia Peng at the University of Washington in Seattle and Federica Di Palma and Jessica Alfoldi at the Broad ...
LA JOLLA, CA - November 17, 2014 - For decades, scientists thought drug addiction was the result of two separate systems in the brain--the reward system, which was activated when a person used a drug, and the stress system, which kicked in during withdrawal.
Now scientists at The Scripps Research Institute (TSRI) have found that these two systems are actually linked. Their findings, published November 17 in the journal Nature Neuroscience, show that in the core of the brain's reward system are specific neurons that are active both with use of and withdrawal from nicotine. ...
Joseph B. Muhlestein, M.D., of the Intermountain Medical Center Heart Institute, Murray, Utah, and colleagues examined whether screening patients with diabetes deemed to be at high cardiac risk with coronary computed tomographic angiography (CCTA) would result in a significant longterm reduction in death, heart attack, or hospitalization for unstable angina. The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014.
Diabetes mellitus is the most important coronary artery disease ...
Yasuo Ikeda, M.D., of Waseda University, Tokyo, Japan, and colleagues examined whether once-daily, low-dose aspirin would reduce the total number of cardiovascular (CV) events (death from CV causes, nonfatal heart attack or stroke) compared with no aspirin in Japanese patients 60 years or older with hypertension, diabetes, or poor cholesterol or triglyceride levels. The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014.
The World Health Organization estimates that annual global mortality ...
DALLAS - November 17, 2014 - Using next generation gene sequencing techniques, cancer researchers at UT Southwestern Medical Center have identified more than 3,000 new mutations involved in certain kidney cancers, findings that help explain the diversity of cancer behaviors.
"These studies, which were performed in collaboration with Genentech Inc., identify novel therapeutic targets and suggest that predisposition to kidney cancer across species may be explained, at least in part, by the location of tumor suppressor genes with respect to one another in the genome," said ...
Washington, D.C.--Silicon is the second most-abundant element in the earth's crust. When purified, it takes on a diamond structure, which is essential to modern electronic devices--carbon is to biology as silicon is to technology. A team of Carnegie scientists led by Timothy Strobel has synthesized an entirely new form of silicon, one that promises even greater future applications. Their work is published in Nature Materials.
Although silicon is incredibly common in today's technology, its so-called indirect band gap semiconducting properties prevent it from being ...
